KURA Kura Oncology, Inc.
Price Chart
Executive Summary
Kura Oncology reported positive first-in-human Phase 1a data for darlifarnib plus adagrasib in KRAS G12C-mutated solid tumors, showing tumor shrinkage in 77% of evaluable patients and ORRs of 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC. The data provide clinical proof-of-mechanism for targeting the mTORC1-RHEB resistance pathway, positioning darlifarnib as a potential combination partner for KRAS inhibitors. The results are being presented at ASCO 2026 and a virtual investor event is scheduled for June 3.
Actionable Insight
The strong early efficacy data across multiple tumor types, including in KRASi-experienced patients, significantly de-risks darlifarnib as a combination partner. Traders should watch for the ASCO presentation on May 30 and the investor event on June 3 for further details and potential partnership or development updates. The stock may see positive momentum, but given the early stage, volatility around these events is expected.
Key Facts
- Tumor shrinkage observed in 77% (20/26) of response-evaluable patients across PDAC, NSCLC, and CRC.
- ORR of 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC.
- Clinical activity seen in heavily pretreated patients, including those with prior KRAS inhibitor exposure.
- Combination was well tolerated with a manageable safety profile; 37% of patients remained on study at data cutoff (March 25, 2026).
- Data to be presented at ASCO 2026 on May 30; virtual investor event on June 3, 2026.
Financial Impact
No financial figures provided; early-stage clinical data with no revenue or guidance impact.
Risk Factors
- Phase 1a data is early-stage; larger trials may not replicate these results.
- Competition from other KRAS inhibitor combinations and resistance mechanisms.
- Darlifarnib 8 mg dose discontinued in this combination, indicating dose-limiting toxicity or lack of benefit at that level.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300885 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
2d ago
|
Press Release
| $8.66 $8.77 | ▲ +1.33% | ▲ +0.93% | $8.74 (+0.98%) |
|
Jun 2, 2026
3d ago
|
Press Release
| $8.97 $8.66 | ▼ −3.51% | ▼ −2.82% | $8.74 (−2.56%) |
|
May 26, 2026
10d ago
|
DEFA14A
| — | awaiting T+1 | — | — |
|
May 26, 2026
10d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 22, 2026
14d ago
|
Insider Cluster
| $10.41 $10.39 | ▼ −0.19% | ▼ −0.15% | $8.74 (−16.04%) |
|
May 12, 2026
24d ago
|
8-K
| $9.48 $9.48 | · 0.00% | ▲ +0.00% | $8.74 (−7.81%) |
|
May 12, 2026
24d ago
|
Press Release
| $9.68 $9.48 | ▼ −2.07% | ▼ −2.64% | $8.74 (−9.71%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $9.68 $9.78 | ▲ +1.03% | ▲ +1.22% | $8.74 (−9.71%) |
|
Apr 10, 2026
8w ago
|
DEFA14A
| $8.72 $9.14 | ▲ +4.82% | ▲ +3.61% | $8.74 (+0.23%) |
|
Mar 5, 2026
13w ago
|
8-K
| $8.51 $8.96 | ▲ +5.29% | ▲ +6.60% | $8.74 (+2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access